Tendyne (system of transkateterny implantation of the mitralny valve)

2020: Announcement

At the end of January, 2020 the Abbott company provided the system of transkateterny implantation of the mitralny Tendyne valve. The solution is intended for correction of the expressed mitralny regurgitation at people who need replacement of a heart valve, but to which open transaction is contraindicated.

The new technology allows to replace the mitralny valve without open transaction, considerably reducing a regurgitation and improving quality of life of patients. Researches showed what at the statement of a regurgitation was not noted at 98.9% of patients of Tendyne, and the efficiency of therapy remained at least within one year.

Abbott provided the system of transkateterny implantation of the mitralny valve

The Tendyne system represents the self-extending valve which is delivered through a small section in a breast, and then is implanted into fragile heart to replace the native mitralny valve. It is designed in such a way that allows surgeons to control precisely its movement during transaction, and can be taken if necessary. Developers claim that the Tendyne system is capable to adapt to different anatomic features of patients.

Professor of department of a heart surgery in University clinic of Bonn doctor Hendrik Treede noted that emergence of Tendyne in the market offers clinical community new option of therapy of a regurgitation of the mitralny valve.

For the first time outside clinical trials of cardiocrew had an opportunity to perform minimum invasive operations on the valve, supported with an excellent profile of security, - Tride added.

Earlier the Abbott company developed technology of endovascular reconstruction of the mitralny valve using the MitraClip device which is also intended for treatment of a mitralny regurgitation. MitraClip is available in the market since 2013.^[1]

Notes